Key result
mRNA COVID-19 vaccine myocarditis features ongoing symptoms in 35% at 12-18 months despite mild clinical severity.
Why the study?
Clinical progression and medium-long term morbidity from myocarditis following mRNA COVID-19 vaccination remained an important but undefined public health concern.
What are the medium-to-long term clinical outcomes and symptom persistence in individuals with myocarditis following mRNA COVID-19 vaccination?
Cohort (n=256)
Yes
What are the medium-to-long term clinical outcomes and symptom persistence in individuals with myocarditis following mRNA COVID-19 vaccination?
While a significant proportion of patients with mRNA COVID-19 vaccine-associated myocarditis experience ongoing symptoms at 12-18 months, the clinical course is generally mild with no deaths, supporting continued vaccine use.
No takes yet. Share an insight, caveat, or question.
May inform counseling on expected symptom duration; leaves open need for prospective validation of long-term outcomes.
Deng et al. (2025) conducted a cohort in Myocarditis following mRNA COVID-19 vaccination (n=256). mRNA COVID-19 vaccination was evaluated on Ongoing symptoms at 12-18 months. Among individuals with myocarditis following mRNA COVID-19 vaccination, 35% reported ongoing symptoms at 12-18 months, though clinical severity remained mild with low hospitalization rates and no deaths.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: